Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

EDURANTâ„¢ 96-Week Phase 3 Safety and Efficacy Data Presented at International AIDS Society Conference

July 19, 2011 By Bio-Medicine.Org

TITUSVILLE, N.J., July 19, 2011 /PRNewswire/ — Janssen
Therapeutics, Division of Janssen Products, LP, presented today
96-week findings from two pivotal Phase 3 clinical trials, known as
ECHO and THRIVE, comparing the efficacy, safety and virology
profile of its non-nucleoside reverse transcriptase inhibitor
(NNRTI) EDURANT™ (rilpivirine) tablets versus efavirenz (EFV)
in antiretroviral treatment-naive, HIV-1-infected adults. The
pooled analysis at 96 weeks showed that 78 percent of patients
achieved and sustained an undetectable plasma viral load (HIV-1 RNA
less than 50 copies/mL) while taking EDURANT as part of combination
therapy. These findings were presented today at the 6th
International AIDS Society Conference on HIV Pathogenesis,
Treatment and Prevention in Rome, Italy.

Pooled ECHO and THRIVE results for EDURANT and EFV, each
administered once daily with a nucleoside/nucleotide background
regimen in treatment-naive, HIV-1-infected adults, showed that 78
percent of patients in both the EDURANT arm (n=686) and the EFV arm
(n=682) reached an undetectable viral load at 96 weeks.  These
data demonstrated non-inferiority (12 percent margin) of EDURANT to
EFV in lowering viral load in this population at 96 weeks,
consistent with the 48-week primary analysis.  Patients taking
EDURANT had a virologic failure rate of 14 percent compared to 8
percent experienced by patients taking EFV, of which 3 percent and
2 percent occurred in the second year of treatment, respectively.
 Upon virologic failure, the emergence of resistance and
cross-resistance to the NNRTI class was higher in the EDURANT arm
compared to the EFV arm.

“Finding safe and tolerable regimens over an extended period of
time is so important in HIV care, and it is encouraging to see that
the 96-week data for EDURANT remain fairly consistent with what we
have seen previously,” said Calvin J. Cohen, M.D., M.Sc., lead
clinical investigator of EDURANT Phase 3 trials and Rese

‘/>”/>

SOURCE

Related Articles Read More >

Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech